NEWPORT, Ky., June 4 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Michael J. Valentino has been named to the position of President and Chief Executive Officer and...
CHESTER, N.J. and SLOUGH, England, Jan. 30 /PRNewswire/ -- Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser") today announced the successful completion of its acquisition of Adams...
NEW YORK, Jan. 29 /PRNewswire/ -- QED International Associates, Inc, administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded...
CHESTER, N.J. and SLOUGH, England, Jan. 24 /PRNewswire-FirstCall/ -- Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser") announced today that it has completed its previously announced cash...
SLOUGH, U.K. and CHESTER, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser") and Adams Respiratory Therapeutics, Inc. (NASDAQ:ARxT) ("Adams...
CHESTER, N.J. and SLOUGH, London, Dec. 10 /PRNewswire-FirstCall/ -- Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser") and Adams Respiratory Therapeutics (NASDAQ:ARxT) ("Adams") today...
NASHVILLE, Tenn., Nov. 14 /PRNewswire/ -- DaySpring Pharma today announced the addition John Thievon and Joe Williams to its Board of Directors. Each brings specific expertise to the...
Strong Pre-Season Sales of New Over-The-Counter (OTC) Mucinex(R) Items Drive CHESTER, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (NASDAQ:ARxT) today announced...
Other Developments Expected to Benefit Fiscal 2008 Financial Results CHESTER, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (NASDAQ:ARxT) today announced that the...
CHESTER, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (NASDAQ:ARxT) is scheduled to announce its sales and earnings results for the fiscal first quarter of 2008...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.